Jennifer Schmitke
Geschäftsführer bei IMV INC.
Aktive Positionen von Jennifer Schmitke
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| IMV INC. | Geschäftsführer | - | - |
Karriereverlauf von Jennifer Schmitke
Ehemalige bekannte Positionen von Jennifer Schmitke
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| EPIZYME, INC. | Corporate Officer/Principal | - | 01.04.2022 |
| BIOGEN INC. | Direktor/Vorstandsmitglied | - | - |
| OMEGA THERAPEUTICS, INC. | Corporate Officer/Principal | - | - |
| MAGENTA THERAPEUTICS | Corporate Officer/Principal | - | - |
Ausbildung von Jennifer Schmitke
| Queen's University | Undergraduate Degree |
| Massachusetts Institute of Technology | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 6 |
| Kanada | 3 |
Operativ
| Corporate Officer/Principal | 3 |
| Undergraduate Degree | 1 |
| Doctorate Degree | 1 |
Sektoral
| Health Technology | 6 |
| Consumer Services | 2 |
| Finance | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| OMEGA THERAPEUTICS, INC. | Health Technology |
| IMV INC. | Health Technology |
| BIOGEN INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
Magenta Therapeutics, Inc.
 Magenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. Its platform includes MGTA-117, MGTA-145, and CD45-ADC. The company was founded by David T. Scadden, Derrick J. Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 17, 2015 and is headquartered in Cambridge, MA. | Health Technology |
- Börse
- Insiders
- Jennifer Schmitke
- Erfahrung
